Rabeprazole Sodium
Product Images NDC 50436-0724

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 50436-0724). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl504360724)

Rabeprazole Sodium delayed-release 20 mg tablets carton label showing a 30 tablet count. Manufactured by Amneal Pharm Pvt Ltd, packaged by Unit Dose Services LLC. The label includes lot number, expiration date placeholders, storage instructions, and an Rx only designation.*

FDA Label Image

01 (Rabeprazole Sodium Delayed Release Tablets 1)

Chemical structure of Rabeprazole Sodium showing its molecular framework, including aromatic rings, nitrogen, sulfur, oxygen atoms, and sodium ion as part of the molecule.*

FDA Label Image

489fe789-figure-02 (Rabeprazole Sodium Delayed Release Tablets 2)

A line graph comparing mean heartburn scores over 28 days for placebo and Rabeprazole Sodium at 10 mg and 20 mg doses. The x-axis represents study days, and the y-axis shows mean heartburn scores ranging from 0 (none) to 4 (very severe). Three distinct lines display symptom trends for each group.*

FDA Label Image

489fe789-figure-03 (Rabeprazole Sodium Delayed Release Tablets 3)

A line graph comparing heartburn scores over a 28-day study period for three groups: placebo, Rabeprazole sodium 10 mg, and Rabeprazole sodium 20 mg. The x-axis represents study days from -14 to 28, and the y-axis shows mean scores of heartburn severity. Scores decrease more notably in the Rabeprazole sodium treatment groups after the start of the study.*

FDA Label Image

489fe789-figure-04 (Rabeprazole Sodium Delayed Release Tablets 4)

A line chart comparing mean heartburn scores over 28 study days between placebo and Rabeprazole Sodium 20mg groups. The x-axis represents study days, ranging from -14 to 28. The y-axis shows heartburn severity scores, from none (0) to very severe (4). The Rabeprazole 20mg group shows a notable decline in mean scores shortly after day 0 compared to placebo.*

FDA Label Image

489fe789-figure-05 (Rabeprazole Sodium Delayed Release Tablets 5)

Line graph comparing mean heartburn scores over a study period for placebo and Rabeprazole Sodium 20 mg groups. The x-axis represents study days from -14 to 28, and the y-axis shows mean scores from 0 (none) to 4 (very severe). The chart includes a legend distinguishing placebo and Rabeprazole Sodium groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.